Colloquially, OCD is known as the doubting disorder. In his new book, Simone Stolzoff explores whether treating that uncertainty with magic mushrooms can help people through it. Adam Strauss is standing in his New York City apartment, holding the limp cord of his headphones, trying to choose between the two MP3 players on his desk: the iPod and the iRiver, its Korean counterpart. He tries different songs, different genres, different instruments. The iRiver tends to sound better overall, but the iPod offers a little more nuance in the midrange. The iPod has a better battery life, but the iRiver still lasts eight hours-- longer than he's ever continuously listened to music. Then again, he's never owned an MP3 player. He goes back and forth, back and forth, testing vocal ranges, button resistance, interface aesthetics. It would be one thing if it were just Adam's decision of which MP3 player to buy. After all, it was 2003, the height of the personal audio device revolution, and Adam was a 29-year-old audiophile. For Adam, it was also other decisions-- what shirt to wear to work, what to order for lunch, even what side of the street to walk down. At one point, in an effort to simplify his decisionmaking process for what to wear, Adam bought 11 identical blue button-down shirts. But he quickly found variations in each shirt's fit and fading. He believed there was a shirt to pick; each morning he would spend 20, 30, then 45 minutes trying to find it. If he could only determine which shirt was best, he could control his fate.

More information Adding us as a Preferred Source in Google by using this link indicates that you would like to see more of our content in Google News results. Psilocybin may help treat issues like PTSD, depression, and alcoholism. Breakthroughs, discoveries, and DIY tips sent six days a week. Psilocybin is the psychoactive compound that puts the "magic" in magic mushrooms . Ingest enough of a fungus like, and users are liable to experience sensory hallucinations, euphoria, and even altered perceptions of time.

Placebo and "knowcebo" effects are a problem. But they can also help people feel better. This week I want to look at where we are with psychedelics, the mind-altering substances that have somehow made the leap from counterculture to major focus of clinical research. Compounds like psilocybin--which is found in magic mushrooms--are being explored for all sorts of health applications, including treatments for depression, PTSD, addiction, and even obesity. Over the last decade, we've seen scientific interest in these drugs explode. But most clinical trials of psychedelics have been small and plagued by challenges.

Phan 1, David L. Dowe 2, Adeel Razi 3,, and Chee-Ming Ting 1, 1 School of Information Technology, Monash University Malaysia, Malaysia 2 Department of Data Science and AI, Faculty of Information Technology, Monash University, Australia 3 Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash University, Australia ABSTRACT Psychedelics, such as psilocybin, reorganise large-scale brain connectivity, yet how these changes are reflected across electrophys-iological (electroencephalogram, EEG) and haemodynamic (functional magnetic resonance imaging, fMRI) networks remains unclear. For each modality, we construct graphs with partial-correlation edges and Pearson-profile node features, and learn subject-level embeddings via graph convolution. An adaptive softmax gate then fuses modalities with sample-specific weights to capture context-dependent contributions. Fusion improves over unimodal and nonadaptive variants, achieving 74.0% accuracy and 76.5% F1 score on meditation, and 76.0% accuracy with 85.8% ROC-AUC on rest. UMAP visualisations reveal clearer class separation for fused em-beddings.

Peter--who asked to have his last name omitted from this story for privacy reasons--is far from alone. A growing number of people are using AI chatbots as "trip sitters"--a phrase that traditionally refers to a sober person tasked with monitoring someone who's under the influence of a psychedelic--and sharing their experiences online. It's a potent blend of two cultural trends: using AI for therapy and using psychedelics to alleviate mental-health problems. But this is a potentially dangerous psychological cocktail, according to experts. While it's far cheaper than in-person psychedelic therapy, it can go badly awry.

The birth of human consciousness may have truly been magic. Scientists have claimed that the consumption of the fungi psilocybin, also known as'magic mushrooms,' influenced pre-human hominids' brains six million years ago. They analyzed dozens of studies involving psilocybin and consciousness, finding the fungi increased connectivity between networks in the frontal brain region associated with expressive language, decision-making and memory. These'significant neurological and psychological effects' may have been the catalase ancient ancestors to interact with each other and the environment - spurring consciousness among our species. The idea that magic mushrooms sparked the pivotal point in humans has been touted by podcaster Joe Rogan, who has referenced the'Stoned Ape Theory' on his show multiple times.

People suffering with depression could soon have a new treatment, in the form of a drug based on a common psychedelic substance found in plants, developers claim. The first patient dosing of the drug, based on the compound DMT (N-Dimethyltryptamine), is being given to'healthy brained' first time drug users in a clinical trial that will examine the impact the substance has on the brain. If successful, the second stage of the trial will see the team experiment with different dosing levels and strategies and eventually treat people with depression. It works by sending the patient on a hallucinogenic trip that acts to'break down' blockages in the mind, that can then be restored with a course of therapy. British biotech firm Small Pharma are running the trial, and CEO Peter Rands told MailOnline said it had the potential to help people not supported by current drugs.

To be fully transparent, I started writing this post in late 2018 in an attempt to detail my own "Things you should be focused on as an investor/consumer in 2019," but the year got ahead of me as interesting projects materialized and so too did my resolution to write more! Some of these projects have already progressed further than I had imagined - I have been fortunate enough to have spent the last two years working, researching & exploring areas that I find most pivotal to improving our quality of life, and we seem to be at an interesting inflection point among all. There are countless applications of Artificial Intelligence either already deployed or in development, with many more envisioned every day. I am most excited for AI that will automate and assist the best interests of the individual: personalized recommendations. I believe said recommendations, those pesky things that currently inundate our platforms with little explanation, should be more transparent and easier to understand.

Scientists may finally be close to understanding the mechanisms behind hallucination. Despite the dramatic perceptual changes that take place during a bout of hallucination, what exactly happens in the brain during these moments has long been a mystery. A new study on drugged mice has found that the phenomena associated with these episodes may be the result of reduced signaling in the visual cortex – not an increase, as was expected. The images revealed that even after taking the drug, the signals being sent were largely similar to those seen in its absence, indicating that the information itself does not change. 'You might expect visual hallucinations would result from neurons in the brain firing like crazy, or by mismatched signals,' says senior author Cris Niell, an associate professor and member of the Institute of Neuroscience at the University of Oregon.

A hallucinating artificial intelligence might see something like this product of Google's Deep Dream algorithm. As artificial intelligence (AI) allows machines to become more like humans, will they experience similar psychological quirks such as hallucinations or depression? And might this be a good thing? Last month, New York University in New York City hosted a symposium called Canonical Computations in Brains and Machines, where neuroscientists and AI experts discussed overlaps in the way humans and machines think. Zachary Mainen, a neuroscientist at the Champalimaud Centre for the Unknown, a neuroscience and cancer research institute in Lisbon, speculated that we might expect an intelligent machine to suffer some of the same mental problems people do.